Digestive Diseases and Sciences

, Volume 50, Issue 12, pp 2323–2329 | Cite as

Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report



Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor. Sixteen patients with active ulcerative colitis (UC; mild in 1 patient, moderate in 11, and severe in 4) were recruited. Enemas containing 150 mg rebamipide per dosing were administered during the daytime after passage of stool, twice a day for 4 weeks. UC disease activity index (UC-DAI), endoscopic activity index (EAI), and Floren's grading (FG) of mucosal biopsy specimens were measured at entry and at 4 weeks. Five of 16 patients did not complete the study, and therefore, final efficacy assessment was done on 11 patients who completed the 4 weeks of treatment. Improvements were observed in UC-DAI (P= 0.0049), EAI (P= 0.0043), and FG (P= 0.0084). There was no serious rebamipide-related side effect in any of the 16 patients. In conclusion, rebamipide topical therapy appears to be effective for the treatment of mildly to moderately active distal UC. Further controlled studies are warranted for this promising drug.


distal ulcerative colitis rebamipide topical therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998, pp 15–95Google Scholar
  2. 2.
    Babb RR: Corticosteroids in ulcerative colitis: A skeptical view. J Clin Gastroenterol 10:365–367, 1988PubMedGoogle Scholar
  3. 3.
    Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48–57, 2000PubMedGoogle Scholar
  4. 4.
    Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 1:28–35, 2003CrossRefPubMedGoogle Scholar
  5. 5.
    Shanahan F: Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622–635, 2001CrossRefPubMedGoogle Scholar
  6. 6.
    Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsijimoto K: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792, 2004CrossRefPubMedGoogle Scholar
  7. 7.
    Treulove SC: Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 2:1072–1077, 1958Google Scholar
  8. 8.
    Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Barbara L: Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32:929–931, 1991PubMedGoogle Scholar
  9. 9.
    Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk ED, Borgen L: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898, 1987PubMedGoogle Scholar
  10. 10.
    Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V: Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: A randomized, double-blind study. Am J Gastroenterol 90:736–739, 1995Google Scholar
  11. 11.
    Hanauer SB (for the U.S. PENTASA Enema Study Group): Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of multicentered placebo-controlled trial. Inflamm Bowel Dis 4:79–83, 1998Google Scholar
  12. 12.
    Selby WS, Bennett MK, Jewell DP: Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 29:231–234, 1984PubMedCrossRefGoogle Scholar
  13. 13.
    Ryder SD, Walker RJ, Jones H, Rhodes JM: Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther 4:333–338, 1990PubMedGoogle Scholar
  14. 14.
    Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J: Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 34:676–679, 1993PubMedGoogle Scholar
  15. 15.
    Bjorck S, Dahlstrom A, Ahlman H: Topical treatment of ulcerative colitis with lidocaine. Scand J Gastroenterol 24:1061–1072, 1989PubMedGoogle Scholar
  16. 16.
    Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106:1429–1435, 1994PubMedGoogle Scholar
  17. 17.
    Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I, Hara K, Kondo T: Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Scand J Gastroenterol 31:985–992, 1996PubMedGoogle Scholar
  18. 18.
    Genta RM: The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 18 (Suppl 1):8–13, 2003CrossRefPubMedGoogle Scholar
  19. 19.
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43 (Suppl 9):5S–13S, 1998PubMedGoogle Scholar
  20. 20.
    Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: A novel therapeutic alternative. Am J Gastroenterol 95:1838–1839, 2000CrossRefPubMedGoogle Scholar
  21. 21.
    Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237–242, 2001PubMedGoogle Scholar
  22. 22.
    Rachmilewitz D on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298:82–86, 1989CrossRefGoogle Scholar
  23. 23.
    Floren C-H, Benoni C, Willen R: Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459–462, 1987PubMedGoogle Scholar
  24. 24.
    Matts SGF: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med, New Ser XXX 120:393–407, 1961Google Scholar
  25. 25.
    Hanauer SB, Present DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3:81–92, 2003PubMedGoogle Scholar
  26. 26.
    Kornbluth A, Marion JF, Salomon P, Janowitz HD: How effective is current medical therapy for severe ulcerative colitis and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 20:280–284, 1995PubMedGoogle Scholar
  27. 27.
    Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977PubMedGoogle Scholar
  28. 28.
    Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441–1449, 1993CrossRefPubMedGoogle Scholar
  29. 29.
    Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K: Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer: Comparison with cimetidine. Dig Dis Sci 40:2469–2472, 1995CrossRefPubMedGoogle Scholar
  30. 30.
    Bamba H, Ota S, Kato A, Miyatani H, Kawamoto C, Yoshida Y, Fujiwara K: Effect of rebamipide on prostaglandin receptors–mediated increase of inflammatory cytokine production by macrophages. Aliment Pharmacol Ther 18 (Suppl 1):113–118, 2003CrossRefPubMedGoogle Scholar
  31. 31.
    Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats. One mechanism for its ulcer healing action? Dig Dis Sci 43:90S–98S, 1998PubMedGoogle Scholar
  32. 32.
    Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43 (Suppl 9):160S–166S, 1998PubMedGoogle Scholar
  33. 33.
    Shimada S, Inoue K, Kuramoto M, Suzuki S, Yamamoto K, Ogawa M: Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy. Dig Surg 20:500–505, 2003CrossRefPubMedGoogle Scholar
  34. 34.
    Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43 (Suppl 9):174S–180S, 1998PubMedGoogle Scholar
  35. 35.
    Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40:775–781, 1997PubMedCrossRefGoogle Scholar
  36. 36.
    Cohen RD, Woseth DM, Thisted RA, Hanauer SB: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263–1276, 2000PubMedGoogle Scholar
  37. 37.
    Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349:350–357, 2003CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Department of EndoscopyNagasaki University Hospital of Medicine and DentistryNagasakiJapan
  2. 2.Department of General MedicineNagasaki University Hospital of Medicine and DentistryNagasakiJapan
  3. 3.Department of Hospital PharmacyNagasaki University Hospital of Medicine and DentistryNagasakiJapan
  4. 4.Department of EndoscopyNagasaki University Hospital of Medicine and DentistryNagasakiJapan

Personalised recommendations